SCHEMBL13604334

SCHEMBL13604334

CC(=O)Nc1cccc(Cn2ccnc2C)c1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
TSHR P16473 1/20 0.62
LMNA P02545 3/20 0.59
ALDH1A1 P00352 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
GLS O94925 1/20 0.52
POLB P06746 1/20 0.52
BRD4 O60885 1/20 0.50
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
MKNK1 Q9BUB5 2/20 0.46
MKNK2 Q9HBH9 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476784 0.83 BRD4 (0.51) KMT2AMEN1TSHRLMNAALDH1A1
SCHEMBL13604333 0.80 MEN1 (0.59) KMT2AMEN1TSHRLMNAALDH1A1
SCHEMBL28745595 0.78 RORC (0.46) KMT2ATSHRLMNAALDH1A1SMN1; SMN2
SCHEMBL14987165 0.77 GLS (0.57) KMT2AMEN1LMNAALDH1A1GLS
SCHEMBL14987181 0.77 GLS (0.57) LMNAALDH1A1SMN1; SMN2GLS
SCHEMBL13604331 0.77 MEN1 (0.55) KMT2AMEN1TSHRLMNAALDH1A1
SCHEMBL14987646 0.76 GLS (0.56) LMNAALDH1A1SMN1; SMN2GLSRAB9A
SCHEMBL13604350 0.75 MEN1 (0.63) KMT2AMEN1TSHRPOLBBRD4
SCHEMBL7819834 0.75 HSD17B10 (0.50) KMT2AMEN1TSHRALDH1A1HSD17B10
SCHEMBL13604352 0.74 MEN1 (0.55) KMT2AMEN1TSHRLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635697-B2 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases SCHERING CORPORATION (US) 2009-12-22 US disclosed
US-7635697-B2 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases SCHERING CORPORATION (US) 2009-12-22 US disclosed